# EDGAR Filing Document

**Accession Number:** 0001287098
**File Stem:** 0001558370-25-008856
**Filing Date:** 2025-6
**Character Count:** 4884
**Document Hash:** 367d493c016c3ce68615617adc31084d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-25-008856.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001558370-25-008856

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250625

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAXCYTE, INC.
- **CENTRAL INDEX KEY:** 0001287098
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522210438
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40674
- **FILM NUMBER:** 251074116

**BUSINESS ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-517-5556

**MAIL ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAXCYTE INC
- **DATE OF NAME CHANGE:** 20040415

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 25, 2025

**MaxCyte, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** |  | **001-40674** |  | **52-2210438** |
| (State or other jurisdiction of <br>incorporation) |  | (Commission File Number) |  | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **9713 Key West Avenue, Suite 400**<br>**Rockville, Maryland** | **20850** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(301) 944-1700**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br>Symbol(s) | Name of each exchange <br>on which registered |
| Common Stock, $0.01 par value | MXCT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01. Other Events.
On June 25, 2025, MaxCyte, Inc. (the "Company") announced that it had applied to the London Stock Exchange plc (the "LSE") to cancel its admission of the Company's common stock (the "Shares") to trading on the AIM market ("AIM") of the LSE (the "AIM Delisting"). It is expected that the AIM Delisting will become effective from 7:00 a.m. U.K. time on June 26, 2025, such that the last date of trading of the Shares on AIM will be June 25, 2025. The AIM Delisting has no impact on the Company's Nasdaq listing of the Shares, which will continue to trade on the Nasdaq Global Select Market under the ticker symbol MXCT.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| 104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MaxCyte, Inc.** | **MaxCyte, Inc.** |
| Date: June 25, 2025 | By: | /s/ Douglas Swirsky |
|  |  | Douglas Swirsky |
|  |  | Chief Financial Officer |

---